SUPPLEMENTARY REFERENCES

1. Park MC, Chung SJ, Park YB, Lee SK. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis. *Scand J Rheumatol*. 2008; 37: 173-178.

2. Sun X, Zhao J, Liu R, Jia R, Sun L, Li X, Li Z. Elevated serum and synovial fluid TNF-like ligand 1A (TL1A) is associated with autoantibody production in patients with rheumatoid arthritis. *Scand J Rheumatol* 42 (2): 97-101, 2013

3. Robak T, Gladalska A, Stepień H. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. *Eur Cytokine Netw* 9 (2): 145-54, 1998.

4. Laustsen JK, Rasmussen TK, Stengaard-Pedersen K, Hørslev-Petersen K, Hetland ML, Østergaard M, Junker P, Hvid M, Deleuran B. Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis. *Arthritis Res Ther* 16 (5): 474, 2014.

5. Gutierrez MJ, Desiderio SV, Wang NY, Darrah E, Cappelli L, Nino G, Jones M, Bingham CO 3rd. Soluble Markers of Antibody Secreting Cell Function as Predictors of Infection Risk in Rheumatoid Arthritis. *J Immunol Res* 2019: 3658215, 2019.

6. Ebrahimi AA, Noshad H, Sadreddini S, Hejazi MS, Mohammadzadeh Sadigh Y, Eshraghi Y, Ghojazadeh M. Serum levels of TNF-alpha, TNF-alphaRI, TNF-alphaRII and IL-12 in treated rheumatoid arthritis patients. *Iran J Immunol* 6 (3): 147-53, 2009.

7. Jung HW, Choi SW, Choi JI, Kwon BS. Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis. *Exp Mol Med* 36 (1): 13-22, 2004.

8. Hashimoto H, Tanaka M, Suda T, Tomita T, Hayashida K, Takeuchi E, Kaneko M, Takano H, Nagata S, Ochi T. Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis. *Arthritis Rheum* 41 (4): 657-62, 1998.

9. Kaplan M, Yuksel M, Ates I, Yaln Kilic ZM, Kilic H, Ates H, Kayacetin E. Are sTWEAK and IL-17A Levels in Inflammatory Bowel Disease Associated with Disease Activity and Etiopathogenesis? *Inflamm Bowel Dis* 22 (3): 615-22, 2016.

10. Avdagić N, Babić N, Šeremet M, Delić-Šarac M, Drače Z, Denjalić A, et al. Tumor necrosis factor-alpha serum level in assessment of disease activity in inflammatory bowel diseases. *Med Glas (Zenica)* 10 (2): 211-6, 2013.

11. Danese S, Katz JA, Saibeni S, Papa A, Gasbarrini A, Vecchi M, et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. *Gut* 52 (10): 1435-41, 2003.

12. Yukawa M, Iizuka M, Horie Y, Yoneyama K, Shirasaka T, Itou H, et al. Systemic and local evidence of increased Fas-mediated apoptosis in ulcerative colitis. *Int J Colorectal Dis* 17 (2): 70-6, 2002.

13. Owczarek D, Cibor D, Głowacki MK, Cieśla A, Mach P. TNF-α and soluble forms of TNF receptors 1 and 2 in the serum of patients with Crohn's disease and ulcerative colitis. *Pol Arch Med Wewn* 122 (12): 616-23, 2012.

14. Funke B, Autschbach F, Kim S, Lasitschka F, Strauch U, Rogler G, et al. Functional characterisation of decoy receptor 3 in Crohn's disease. *Gut* 58 (4): 483-91, 2009.

15. Maarouf A, Stephan D, Ranjeva MP, Ranjeva JP, Pelletier J, Audoin B, et al. High levels of serum soluble TWEAK are associated with neuroinflammation during multiple sclerosis. *J Transl Med* 17 (1): 51, 2019.

16. Ribeiro CM, Oliveira SR, Alfieri DF, Flauzino T, Kaimen-Maciel DR, Simão ANC, et al. Tumor necrosis factor alpha (TNF-α) and its soluble receptors are associated with disability, disability progression and clinical forms of multiple sclerosis. *Inflamm Res* 68 (12): 1049-1059, 2019.

17. Liu GZ, Gomes AC, Putheti P, Karrenbauer V, Kostulas K, Press R, et al. Increased soluble 4-1BB ligand (4-1BBL) levels in peripheral blood of patients with multiple sclerosis. *Scand J Immunol* 64 (4): 412-9, 2006.

18. Rinta S, Kuusisto H, Raunio M, Paalavuo R, Levula M, Lehtimäki T, et al. Apoptosis-related molecules in blood in multiple sclerosis. *J Neuroimmunol* 205 (1-2): 135-41, 2008.

19. Mameli G, Cocco E, Frau J, Arru G, Caggiu E, Marrosu MG, et al. Serum BAFF levels, Methypredsinolone therapy, Epstein-Barr Virus and Mycobacterium avium subsp. paratuberculosis infection in Multiple Sclerosis patients. *Sci Rep* 6: 29268, 2016.

20. Boylan MT, Crockard AD, McDonnell GV, McMillan SA, Hawkins SA. Serum and cerebrospinal fluid soluble Fas levels in clinical subgroups of multiple sclerosis. *Immunol Lett* 78 (3): 183-7, 2001.

21. Masuda H, Mori M, Uchida T, Uzawa A, Ohtani R, Kuwabara S. Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in

multiple sclerosis and neuromyelitis optica spectrum disorder. *J Neuroimmunol* 305: 102-107, 2017

22. Chen J, Wei L, Xia Y. Roles of tumour necrosis factor-related weak inducer of apoptosis/fibroblast growth factor-inducible 14 pathway in lupus nephritis. *Nephrology (Carlton)* 22 (2): 101-106, 2017.

23. Xu WD, Chen DJ, Li R, Ren CX, Ye DQ. Elevated plasma levels of TL1A in newly diagnosed systemic lupus erythematosus patients. *Rheumatol Int* 35 (8): 1435-7, 2015.

24. Patel M, Oni L, Midgley A, Smith E, Tullus K, Marks SD, et al. Increased concentration of plasma TNFR1 and TNFR2 in paediatric lupus nephritis. *Lupus* 25 (9): 1040-4, 2016.

25. Mahmoud RA, El-Gendi HI, Ahmed HH. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus. *Clin Biochem* 38 (2): 134-41, 2005.

26. Kim KJ, Baek IW, Yoon CH, Kim WU, Cho CS. Elevated levels of soluble CD40 ligand are associated with antiphospholipid antibodies in patients with systemic lupus erythematosus. *Clin Exp Rheumatol* 35 (5): 823-830, 2017.

27. Tinazzi E, Puccetti A, Gerli R, Rigo A, Migliorini P, Simeoni S, et al. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment. *Int Immunol* 21 (3): 237-43, 2009.

28. Gu L, Xu L, Zhang X, Tan W, Wang H, Zhang M. Correlation of circulating glucocorticoid-induced TNFR-related protein ligand levels with disease activity in patients with systemic lupus erythematosus. *Clin Dev Immunol* 2012: 265868, 2012.

29. Font J, Pallares L, Martorell J, Martinez E, Gaya A, Vives J, et al. Elevated soluble CD27 levels in serum of patients with systemic lupus erythematosus. *Clin Immunol Immunopathol* 81 (3): 239-43, 1996.

30. Liphaus BL, Kiss MHB, Carrasco S, Palmeira P, Goldenstein-Schainberg C, Carneiro-Sampaio M. Increased serum sFas, sTRAIL, and reduced sFasL in juvenile-onset systemic lupus erythematosus. *Clin Rheumatol* 36 (12): 2847-2852, 2017.

31. Chen JM, Guo J, Wei CD, Wang CF, Luo HC, Wei YS, Lan Y. The association of CD40 polymorphisms with CD40 serum levels and risk of systemic lupus erythematosus. *BMC Genet* 16: 121, 2015.

32. Wang S, Shi Y, Yang M, Ma J, Tian J, Chen J, et al. Glucocorticoid-induced tumor necrosis factor receptor family-related protein exacerbates collagen-induced arthritis by enhancing the expansion of Th17 cells. *Am J Pathol* 180 (3): 1059-67, 2012.